Does VIMSELTINIB Cause Product dose omission issue? 12 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Product dose omission issue have been filed in association with VIMSELTINIB (ROMVIMZA). This represents 7.1% of all adverse event reports for VIMSELTINIB.
12
Reports of Product dose omission issue with VIMSELTINIB
7.1%
of all VIMSELTINIB reports
0
Deaths
1
Hospitalizations
How Dangerous Is Product dose omission issue From VIMSELTINIB?
Of the 12 reports, 1 (8.3%) required hospitalization.
Is Product dose omission issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VIMSELTINIB. However, 12 reports have been filed with the FAERS database.
What Other Side Effects Does VIMSELTINIB Cause?
Fatigue (57)
Pruritus (23)
Swelling face (23)
Peripheral swelling (22)
Nausea (20)
Headache (17)
Periorbital swelling (17)
Eye swelling (16)
Rash (15)
Arthralgia (13)
What Other Drugs Cause Product dose omission issue?
DUPILUMAB (18,189)
USTEKINUMAB (9,405)
GUSELKUMAB (9,267)
LENALIDOMIDE (8,145)
MEPOLIZUMAB (5,873)
TOFACITINIB (5,646)
VOXELOTOR (5,122)
BELIMUMAB (4,671)
SECUKINUMAB (4,572)
APREMILAST (4,460)
Which VIMSELTINIB Alternatives Have Lower Product dose omission issue Risk?
VIMSELTINIB vs VINBLASTINE
VIMSELTINIB vs VINCRISTINE
VIMSELTINIB vs VINDESINE
VIMSELTINIB vs VINORELBINE
VIMSELTINIB vs VINORELBINE\VINORELBINE